Related Experiment Video
Updated: Jun 12, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
[Transition of classical systemic treatments to etanercept]
1Servei de Dermatologia, Hospital Universitari Germans Trias i Pujol, Badalona, Universidad Autónoma de Barcelona, Barcelona, España. cferrandiz.germanstrias@gencat.cat
Abstract:
The transition of classical systemic treatments to etanercept is an attractive strategy and is, a priori, useful in many clinical practice situations. However, the experience published in this regards has been limited to isolated cases and small series. Transition between methotrexate and etanercept seems to be safe and effective. It should be slowly introduced until etanercept has achieved a sufficient response (4-8 weeks). It even would be possible to try to adjust a long-term combination of low doses of methotrexate. The strategy would be similar for acitretine, the adverse effects characteristic of acitretine being its limitation. Transition from narrow band phototherapy or cyclosporine is, based on the existing experience, effective, although it should be limited to certain moments of the disease due to the uncertainty of the long-term safety of these associations.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Nephrotic Syndrome II : Assessment and Medical Management
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents